AI’s Billion-Dollar Impact: Measurable BP Reduction & ROI
Uncontrolled hypertension is a global health crisis, but for investors, it’s simpler: it’s an economic problem that costs…
AI for Hypertension: Which Vendors Prove Adherence?
Medication non-adherence in hypertension isn’t a small problem, it costs healthcare systems billions of dollars, worsens patient outcomes,…
Cardiac AI: Validating Clinical Outcomes for Investor Growth
The AI market for chronic disease is a mess. Everyone claims they can deliver cardiovascular improvements, but when…